Tech Company Financing Transactions
Arisaph Pharmaceuticals Funding Round
Private investors participated in a $10 million funding round for Arisaph Pharmaceuticals. The round was announced on 11/1/2013.
Transaction Overview
Company Name
Announced On
11/1/2013
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for solicitation details, if applicable.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 High St. 1202
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Overview
Arisaph is an emerging biopharmaceutical company focused on developing novel therapies for cancer, cardiovascular disease and diabetes. The company utilizes proprietary drug discovery platforms to develop differentiated medicines that are highly potent and act selectively on validated targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Kiritsy
Chief Scientific Officer
William Bachovchin
VP - Finance
Joseph Suarez
Browse more venture capital transactions:
Prev: 11/1/2013: Kumu Networks venture capital transaction
Next: 11/1/2013: Greengage Mobile venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs